Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BCMA-targeted antibody-drug conjugate

DRUG CLASS:

BCMA-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

belantamab mafodotin-blmf (3)

belantamab mafodotin-blmf (3)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	belantamab mafodotin-blmf Sensitive: A1 - Approval belantamab mafodotin-blmf Sensitive : A1	belantamab mafodotin-blmf Sensitive: A1 - Approval belantamab mafodotin-blmf Sensitive : A1
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	HDP-101 Sensitive: D – Preclinical HDP-101 Sensitive : D	HDP-101 Sensitive: D – Preclinical HDP-101 Sensitive : D
TNFRSF17 expression	Lymphoma	TNFRSF17 expression	Lymphoma	belantamab mafodotin-blmf Sensitive: D – Preclinical belantamab mafodotin-blmf Sensitive : D	belantamab mafodotin-blmf Sensitive: D – Preclinical belantamab mafodotin-blmf Sensitive : D